ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2020
Brain imaging measurements of fibrillar amyloid-β burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE ε4 allele.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 37 citations in OpenAlex.
- Metabolism fluctuation coupling can track the progression of dementia and describe MST1 gene-related pathology.Communications medicine · 2026Article
- Apolipoprotein E and Alzheimer's disease pathology in a diverse autopsy study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- The Risk of Alzheimer Disease in APOE4 Homozygotes.JAMA neurology · 2025Article
- APOE4 impact on soluble and insoluble tau pathology is mostly influenced by amyloid-β.Brain : a journal of neurology · 2025Article
- Impact of APOE4-related dementia risk in underrepresented groups from the All of Us research program.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Apolipoprotein E in Alzheimer's disease trajectories and the next-generation clinical care pathway.Nature neuroscience · 2024Review
- APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease.Nature medicine · 2024Article
- A review of the flortaucipir literature for positron emission tomography imaging of tau neurofibrillary tangles.Brain communications · 2024Review
- APOE ε4 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly.Alzheimer's research & therapy · 2023Article
- APOE effects on regional tau in preclinical Alzheimer's disease.Molecular neurodegeneration · 2023Article
- APOE genotype, hippocampus, and cognitive markers of Alzheimer's disease in American Indians: Data from the Strong Heart Study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Article
- Memory markers in the continuum of the Alzheimer's clinical syndrome.Alzheimer's research & therapy · 2022Article
- Correlations between APOE4 allele and regional amyloid and tau burdens in cognitively normal older individuals.Scientific reports · 2022Article
- Network dysfunction in cognitively normal APOE ε4 carriers is related to subclinical tau.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Article
- Sex modifies APOE ε4 dose effect on brain tau deposition in cognitively impaired individuals.Brain : a journal of neurology · 2021Article
- Developing methods to detect and diagnose chronic traumatic encephalopathy during life: rationale, design, and methodology for the DIAGNOSE CTE Research Project.Alzheimer's research & therapy · 2021Article
- Clinical validity of increased cortical uptake of [European journal of nuclear medicine and molecular imaging · 2021Review
- Recent Advances in Imaging of Preclinical, Sporadic, and Autosomal Dominant Alzheimer's Disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021Review
- Brain health registry GenePool study: A novel approach to online genetics research.Alzheimer's & dementia (New York, N. Y.) · 2021Article
- Resilience to Plasma and Cerebrospinal Fluid Amyloid-β in Cognitively Normal Individuals: Findings From Two Cohort Studies.Frontiers in aging neuroscience · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
Abstract
introductionWe previously characterized associations between brain imaging measurements of amyloid-β (Aβ) plaque burden and apolipoprotein E (APOE) ε4 gene dose in a small number of cognitively unimpaired late-middle-aged APOE ε4 homozygotes (HMs), heterozygotes (HTs), and noncarriers (NCs). We now characterize cross-sectional Aβ plaque, tau tangle, and cortical atrophy (neurodegeneration) measurements, classifications, and associations with age in a larger number of unimpaired HMs, HTs, and NCs over a wider age range.
methodsWe analyzed
resultsAβ PET measurements rose, plateaued at the respective ages of 68 and 76, and then declined with age in unimpaired HM and HT groups. Compared with NCs, these two groups began to have significantly higher Aβ PET measurements at ages 62 and 70, respectively, and no longer had significantly higher measurements by ages 71 and 78, respectively. They began to have significantly higher entorhinal cortex tau PET measurements at ages 66 and 70, respectively, and no longer had significantly higher measurements by ages 74 and 78, respectively. Brain atrophy measurements tended to decline slowly with age in all three genetic groups. Their elevated tau PET measurements were attributable to those with positive Aβ PET scans. 41.0%, 18.0%, and 5.0% of the 47- to 70-year-old HMs, HTs, and NCs and 25.0%, 79.0%, and 38.0% of the 71- to 86-year-old HMs, HTs, and NCs had positive Aβ PET scans, and the long-term recall memory scores are significantly higher in the older HMs than in HT and NC groups, suggesting resistance to Aβ deposition in those HMs who remained unimpaired at older ages.
conclusionsThis study provides information about Aβ plaque burden, tau tangle burden, and neurodegeneration in cognitively unimpaired persons at three levels of genetic risk for AD. Unimpaired APOE ε4 HMs can be studied before their 70s to evaluate the understanding of factors, processes, and interventions involved in the predisposition to and prevention of AD, and after their 70s, to discover factors, processes, and interventions involved in the resilience or resistance to and prevention of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.